NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD

NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD

Abstract To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the...

Full description

Saved in:
Bibliographic Details
Main Authors: Sergey N. Avdeev, Viliya V. Gaynitdinova, Zamira M. Merzhoeva, Galiya S. Nuralieva, Evgeniy A. Tarabrin, Zelimkhan G. Berikkhanov, Lidiya Y. Nikitina, Tatiana Y. Gneusheva, Elizaveta S. Sokolova, Rifat M. Ainetdinov, Anna A. Proshkina, Kirill S. Ataman, Qingyun Ma
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Chronic obstructive pulmonary disease
Pulmonary hypertension
Biomarkers, NT-proCNP
Online Access:https://doi.org/10.1038/s41598-025-08059-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the COPD patients were divided into group of patients without PH (SPAP < 40 mmHg, n = 42) and group of patients with PH (SPAP ≥40 mmHg, n = 52). Significant differences in NT-proCNP levels were found in patients with and without PH (3.63 ± 0.95 pg/mL vs. 1.42 ± 0.35 pg/mL, p < 0.001). Statistically significant correlations were shown between NT-proCNP levels and SPAP (r = 0.77, p < 0.001), mMRC dyspnea score (r = 0.42, p = 0.001), CAT score (r = 0.60, p < 0.001), and SpO2 (r = − 0.47, p = 0.001). Pulmonary hypertension in COPD patients was associated with higher plasma NT-proCNP levels.
ISSN:2045-2322

Similar Items